	US 12,247,047 B2
	Arnatar compounds and methods for enhanced cellular uptake
Derek Steiner, Del Mar, CA (US); Xuehai Liang, Del Mar, CA (US); and Yangfeng Wang, Carlsbad, CA (US)
Assigned to ARNATAR THERAPEUTICS, INC, San Diego, CA (US)
Filed by Arnatar Therapeutics, Inc, San Diego, CA (US)
Filed on Aug. 1, 2024, as Appl. No. 18/792,393.
Application 18/792,393 is a continuation of application No. PCT/US2023/084692, filed on Dec. 18, 2023.
Claims priority of provisional application 63/433,730, filed on Dec. 19, 2022.
Claims priority of provisional application 63/533,273, filed on Aug. 17, 2023.
Claims priority of provisional application 63/602,245, filed on Nov. 22, 2023.
Prior Publication US 2024/0417422 A1, Dec. 19, 2024
Int. Cl. C07H 21/02 (2006.01); A61K 47/54 (2017.01); C07H 15/08 (2006.01)

CPC C07H 21/02 (2013.01) [A61K 47/549 (2017.08); C07H 15/08 (2013.01)]

8 Claims

1. A compound having the structure of formula (0a), (Ia) or (IIa):

Wherein

X is a hydroxy-protecting group or an H atom,

Y is a hydroxy-protecting group, an H atom, a payload, or a solid support,

Oligo represents a modified and/or unmodified oligonucleotide

R¹is selected from any of hydroxy-protecting groups and H atom,

R⁶represents a hydroxy-protecting group, and

R⁷represents a moiety of formula (VI):

wherein in R7

R represents a solid support, an amino-protecting group, a hydroxy-protecting group,

or an H atom,

Z represents NH or O, and

R⁸represents a linear or branched alkylene having from 1 to 8 carbon atoms and/or a cycloalkylene having from 5 to 8 carbon atoms.